And then you had multiple mechanisms of action and multiple scaffolds ... In that case, it took seven years to get in 2012 to TRIKAFTA. I'm not saying it will happen that fast, but nonetheless ...

Neither Trikafta nor Alfytrek address NBD1 ... desire for more treatment options for CF patients, support for a new mechanism of action that could provide clinically meaningful benefit for ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...

It is also dosed just once a day, while Trikafta needs twice-daily dosing. The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from ...

EU countries have agreed on a market correction mechanism which will limit episodes of extraordinarily high gas prices in the EU and thus reduce the impact of price hikes on citizens and the economy.

My CF consists of two very rare genetic mutations. We had all heard of Trikafta being around the corner, but I had been told so many times that it wasn’t designed for someone with my mutations. So, ...

TRIKAFTA was first consented by Medsafe in 2021 for use in people with CF aged 6 years and older with at least one F508del mutation in the CFTR gene.

For Tanya Vavouri, group leader at the Josep Carreras Leukaemia Research Institute, an expert in epigenetic processes and their transmission who was not involved in this work, “it is a very good study ...

The Antikythera mechanism is one of the most mysterious and fascinating ancient inventions from the ancient world. Largely a mystery until the last few decades, the device has fascinated ...

Membrane Biochemistry & Biophysics, Bijvoet Center for Biomolecular Research, Department of Chemistry, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands Membrane Biochemistry & ...